Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | NPC1 | O15118 | 7/20 | 0.77 |
| ▸ | RAB9A | P51151 | 7/20 | 0.77 |
| ▸ | RRM1 | P23921 | 4/20 | 0.77 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.77 |
| ▸ | IDO1 | P14902 | 2/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | G6PD | P11413 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16713131 | 1.00 | PAX8 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1679411 | 1.00 | PAX8 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL800974 | 1.00 | PAX8 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL683715 | 0.90 | MEN1 (0.85) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2847708 | 0.90 | MEN1 (0.85) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10785019 | 0.87 | MEN1 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL11406319 | 0.87 | MEN1 (1.00) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16724452 | 0.86 | PAX8 (0.76) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14223812 | 0.85 | MEN1 (0.81) | PAX8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16582347 | 0.85 | PAX8 (0.74) | PAX8MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| CN-119792523-A | Application of KDM5B inhibitor in preparation of medicine for treating EBV-related epithelial tumors | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-04-11 | — | — | CN | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | claimed |
| CN-118581026-A | Culture medium for in-vitro amplification of functional islet organoids | 蚌埠医学院第一附属医院（蚌埠医学院附属肿瘤医院） | 2024-09-03 | — | — | CN | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| CN-114634908-A | Direct reprogramming of human somatic cells into selected (predetermined) differentiated cells using functionalized nanoparticles | 斯特姆詹尼克斯公司 | 2022-06-17 | — | — | CN | claimed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250368949-A1 | SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2025-12-04 | — | — | US | disclosed |
| US-20250305055-A1 | PROGNOSTIC/PREDICTIVE BREAST CANCER SIGNATURE | CORNELL UNIVERSITY | 2025-10-02 | — | — | US | disclosed |
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2025122992-A1 | CELLULAR ANCESTRY SIGNATURES FOR SUBTYPING CANCERS PRIORITY | CORNELL UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| CN-114480259-A | Culture medium and induction method for inducing totipotent stem cells of mice | 中山大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114174496-A | Compositions and methods for generating hair cells by inhibiting epigenetic targets | 频率医疗公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2, ATXN2L, ATXN10 | PAX8 1565/4885MEN1 3102/4885KMT2A 2285/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | PAX8 1436/4885MEN1 338/4885KMT2A 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.